Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

161. Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice

Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice 28680466 2018 11 13 1753-495X 10 2 2017 Jun Obstetric medicine Obstet Med Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice. 74-78 10.1177/1753495X16685684 Little evidence exists for the optimal management of atrial fibrillation with a structurally normal heart in pregnancy. A survey was sent to members of two associations (...) to obtain input on optimal management of atrial fibrillation in pregnancy. The survey presented four cases with respect to (1) baseline investigations; (2) rate versus rhythm control; (3) chemical versus electrical cardioversion; and (4) anticoagulation. Sixty-one responders from 11 countries participated. High agreement was noted for baseline investigations. A quarter (25%) of participants chose elective cardioversion even with a reversible precipitant. Electrical cardioversion was preferred over

Obstetric medicine2017 Full Text: Link to full Text with Trip Pro

162. Should we recommend catheter ablation to all patients with persistent atrial fibrillation?

Should we recommend catheter ablation to all patients with persistent atrial fibrillation? Should we recommend catheter ablation to all patients with persistent atrial fibrillation? - Evidently Cochrane Search and hit Go By January 9, 2017 // In this guest blog for healthcare professionals caring for people with atrial fibrillation (AF), Vinod Achan (@surreyHEART), Consultant Cardiologist at Frimley Park Hospital, reflects on a Cochrane review on the effectiveness and safety of ablation (...) as an alternative to drug treatment and sets these treatments in context. Atrial fibrillation (AF) is the most common arrhythmia and increases the chance of stroke 5-fold Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, increasing with age such that 20% of >80 year olds may be in permanent AF. AF may be: Paroxysmal (intermittent, recurrent, and self-terminating; accounts for 35 to 66% of all cases of AF), Persistent (duration greater than 7 days, will not self-terminate

Evidently Cochrane2017

163. Atrial Fibrillation

Atrial Fibrillation Atrial Fibrillation - Clinical Practice Guideline -- Clinical Recommendation Welcome Search Search Specify your search AAFP.org Patient Care Clinical Practice Guideline Atrial Fibrillation Pharmacologic Management of Newly Detected Atrial Fibrillation (Developed by the AAFP, April 2017) The guideline, Pharmacologic Management of Newly Detected Atrial Fibrillation was developed by the American Academy of Family Physicians. It was approved by the Board of Directors in April (...) 2017. Key Recommendations Rate control is recommended in preference to rhythm control for the majority of patients who have atrial fibrillation. Preferred options for rate control therapy include non-dihydropyridine calcium channel blockers and beta blockers. Rhythm control may be considered for certain patients based on patient symptoms, exercise tolerance, and patient preferences. Lenient rate control (<110 beats per minute resting) is recommended over strict rate control (<80 beats per minute

American Academy of Family Physicians2017

164. The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation

The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation SPECIAL REPORT The Society of Thoracic Surgeons 2017 Clinical Practice Guidelines for the Surgical Treatment of Atrial Fibrillation Vinay Badhwar, MD, J. Scott Rankin, MD, Ralph J. Damiano, Jr, MD, A. Marc Gillinov, MD, Faisal G. Bakaeen, MD, James R. Edgerton, MD, Jonathan M. Philpott, MD, Patrick M. McCarthy, MD, Steven F. Bolling, MD, Harold G. Roberts, MD, Vinod H. Thourani (...) of CaliforniaLosAngelesDavidGeffenSchoolofMedicine,LosAngeles,California(RJS);andTheSocietyofThoracicSurgeons,Chicago, Illinois (SF) Executive Summary Surgical ablation for atrial ?brillation (AF) can be per- formed without additional risk of operative mortality or major morbidity, and is recommended at the time of concomitant mitral operations to restore sinus rhythm. (Class I, Level A) Surgical ablation for AF can be performed without additional operative risk ofmortality or majormorbidity, and is recommended at the time of concomitant

Society of Thoracic Surgeons2017

165. Pharmacologic management of newly detected atrial fibrillation.

Pharmacologic management of newly detected atrial fibrillation. Pharmacologic management of newly detected atrial fibrillation. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group (...) at . TIMESTAMPS Search Sign In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Summary NGC:011237 2017 Apr NEATS Assessment Pharmacologic management of newly detected atrial fibrillation. American Academy of Family Physicians

National Guideline Clearinghouse (partial archive)2017

166. Systematic review: Stroke rates vary substantially across cohorts of patients with atrial fibrillation

Systematic review: Stroke rates vary substantially across cohorts of patients with atrial fibrillation Stroke rates vary substantially across cohorts of patients with atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stroke rates vary substantially across cohorts of patients with atrial fibrillation Article Text Prognosis Systematic review Stroke rates vary substantially across cohorts of patients with atrial fibrillation Luciano A Sposato 1 , 2 , Gustavo Saposnik 3 , 4 Statistics from Altmetric.com Commentary on: Quinn GR , Severdija

Evidence-Based Medicine (Requires free registration)2017

167. Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH

Observational study: In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7?8 weeks after ICH In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In patients with intracerebral haemorrhage and concomitant atrial fibrillation, optimal timing of reinitiating anticoagulants may be 7–8 weeks after ICH Article Text Therapeutics

Evidence-Based Medicine (Requires free registration)2017

168. Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation

Cohort study: Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients with atrial fibrillation Article Text Therapeutics/Prevention Cohort study Resumption of anticoagulation after major bleeding decreases the risk of stroke in patients

Evidence-Based Medicine (Requires free registration)2017

169. Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation

Cohort study: Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our (...) . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Apixaban may have lower risk of GI bleeding compared with dabigatran and rivaroxaban in patients with atrial fibrillation Article

Evidence-Based Medicine (Requires free registration)2017

170. Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation

Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation EXPERT CONSENSUS DECISION PATHWAY 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force Periprocedural Management of Anticoagulation Writing Committee John U. Doherty, MD, FACC, Chair Ty J. Gluckman, MD, FACC William J (...) factors as they come to their own decision on a treatment plan to be recom- mended and discussed with their patients. There may be multiple pathways that can be taken for treatment decisions, and the goal is to help clinicians make a more informed decision. JamesL.Januzzi,JR,MD,FACC Chair, ACC Task Force on Clinical Expert Consensus Documents 1. INTRODUCTION Atrial ?brillation (AF) is the most common sustained arrhythmia worldwide (1), substantially increasing in prevalence withage(2) andoccurringin

American College of Cardiology2017

171. Screening for Atrial Fibrillation: 2017 European Heart Rhythm Association (EHRA) Consensus Document

Screening for Atrial Fibrillation: 2017 European Heart Rhythm Association (EHRA) Consensus Document Screeningforatrialfibrillation:aEuropean HeartRhythmAssociation(EHRA)consensus documentendorsedbytheHeartRhythm Society(HRS),AsiaPacificHeartRhythm Society(APHRS),andSociedad LatinoamericanadeEstimulaci onCard iaca y Electrofisiolog ia(SOLAECE) GeorgesH.Mairesse 1 *(Chair,Belgium),PatrickMoran 2 (Ireland), IsabelleC.VanGelder 3 (TheNetherlands),ChristianElsner 4 (Germany), MartenRosenqvist 5 (...) Management School, Clinical Leadership, Antwerp, Belgium; 14 Arrhythmia Alliance & AF Association, Unit 6B, Essex House, Cromwell Business Park, Chipping Norton, Oxfordshire OX7 5SR, UK; 15 Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark; 16 Institute of Cardiovascular Sciences, University of Birmingham

Heart Rhythm Society2017

172. 2017 Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: A Joint Consensus Document from EHRA and ESC Working Group on Thrombosis

2017 Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: A Joint Consensus Document from EHRA and ESC Working Group on Thrombosis Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (...) search filter search input Article Navigation Close mobile search navigation Article navigation November 2017 Article Contents Article Navigation Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm

Heart Rhythm Society2017

173. Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

Dabigatran for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

DynaMed Plus2017

178. Warfarin for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

Warfarin for thromboembolic prophylaxis in atrial fibrillation: Evidence profile

DynaMed Plus2017

179. Thromboembolic prophylaxis in atrial fibrillation: Comparing Treatment Options

Thromboembolic prophylaxis in atrial fibrillation: Comparing Treatment Options

DynaMed Plus2017